Maternal and neonatal antibody levels on pertussis vaccination in pregnant women on immune-modulating therapy for rheumatic disease
Authors' conclusion
These preliminary data indicate no major differences in IgG antibody levels on maternal Tdap vaccination in pregnant women with or without immune-modulating treatment, although our findings suggest that TNFis during pregnancy induce lower maternal anti-pertussis-specific protective antibody levels in newborns.
Study context
- Population
- Pregnant patients with rheumatic disease receiving maternal tetanus-diphtheria-and-acellular-pertussis (Tdap) vaccination in the late-second or early-third trimester66 patients enrolled
- Participants
- 46 / 20 / 53
- Exposure
- TNFi-exposed vs TNFi-unexposed pregnant patients with rheumatic disease, and vs healthy Tdap-vaccinated mother-infant pairs
- TNFi-exposedn = 46
- TNFi-unexposedn = 20reference
- Healthy mothersn = 53
- Outcome
- IgG antibody levels against Tdap-included antigens in mothers and cord sera
Methodological detailspilot study, historical comparator cohort
- Pilot study
- Historical comparator cohort
Main finding
As reported in the abstract
Cord serum anti-pertussis toxin IgG
Observational data: associations, not effects.
Further findings
Maternal IgG antibody levels before Tdap vaccination and 3 months after delivery
- No major differences between TNFi-exposed and unexposed mothers
Cord serum IgG against filamentous haemagglutinin, pertactin, tetanus toxoid and diphtheria toxoid
- Similar differences observed
Original publication
Maternal and neonatal antibody levels on pertussis vaccination in pregnant women on immune-modulating therapy for rheumatic disease. RMD Open. Published 28 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →